The China AI for Pharma R&D Conference (CAPR2023) was held in Shanghai on May 25-26. The conference focused on the latest progress in AI-enabled drug research and development in recent years. During the event, AIxplorerBio demonstrated its multi-target sm
Recently, a further collaboration between Suozhi Bio and Baitu Life Sciences has been announced. The two companies will be conducting joint research in the area of inflammatory bowel disease (IBD) by leveraging AIxplorerBio’s AIxMol new drug development technology platform and BioMap’s AIGP platform to carry out cooperative dual-target exploration.
Since May 2022, AIxplorerBio has established a broad collaboration with Baidu's PaddleHelix in multiple areas, including de novo molecule design and optimization as well as draggability parameter predictions. In the evaluation of compounds’ druggability, AIxplorerBio has target-optimized PaddleHelix’s HelixADMET and integrated it into the company's AI drug discovery platform (AIxMol®). The platform has been successfully applied to the company's pipeline projects, helping the company deliver three Pre-clinical Compound Candidate (PCC) molecules in just 18 months. AIxplorerBio will continue to collaborate with industry leaders like Baidu to improve the functionality and efficiency of its AIxMol® platform to develop differentiated products more efficiently.
On August 22, AIxplorerBio announced that the company had successfully launched AIxMolTM, its molecular design and optimization platform. AIxMolTM is committed to empowering internal drug development pipeline by combining Artificial Intelligence (AI) with2022.08.22
Editor's Note: Recently, the VC Beat Research under VBDATA released the "2022 AI+ New Drug Research And Development Industry Research Report" ,From Drug Discovery to Full-Scenario Layout, AI+ New Therapy has become a New Blue Ocean in the Market", whic2022.08.05
AIxplorerBIO and the Institute of Immunology at Tsinghua University recently reached a strategic collaboration agreement, in the field of autoimmunity on the pathogenesis of selected diseases, the selection and validation of relevant drug targets, and oth2022.07.25
In recent years, with the advance in technology, there also comes new challenges and opportunities from personalized treatment to disease prevention. Among the emerging technologies, artificial intelligence (AI) has received increasing attention in the f2022.07.06
On the evening of June 22, 2022, the first session of the Open Class on AIPHARMS《Frontier Progress in AI Drug Design》, was launched online. Dr. David Xu, founder and CEO of AIxplorerbio, as a special host, delivered an opening speech and moderated the dis2022.06.30
On May 18, AIxplorerBio announced a broad collaboration with PaddleHelix. The two parties will leverage their strengths and collaborate in the fields of de novo molecular design and druggability evaluation, to accelerate new AI-powered drug research and d2022.05.18